HALO Diagnostics
- Company typePrivate
- Founded2023
- HeadquartersMenlo Park, United States
- Headcount101–250
- GTM typeB2C
- OfferingServices
HALO Diagnostics firmographics
Firmographics- Name
- HALO Diagnostics
- Legal name
- HALO Precision Diagnostics
- Website
- https://halodx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
HALO Diagnostics industry classification
Industry- Product category
- Precision Diagnostics
- NAICS
- Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Health Services (8000), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB)
- akta.pro secondary industries
- Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE), Software as a Medical Device (SaMD) – Clinical Decision & Diagnostic Software (HLACANAD), Cardiac Diagnostic Centers (Echo/Stress Testing/Holter) (HLAFAKAE)
Keywords
Where HALO Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
HALO Diagnostics business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Imaging Services: Revenue generated from advanced imaging services including MRI scans, PET/CT scans, CT scans, ultrasound scans, and specialized imaging for prostate, breast, lung, cardiac, and neurological conditions. Services are billed to insurance or patients directly.
- Genetic and Genomic Testing: Revenue from cancer predisposition genetic testing, biomarker testing, and genomic profiling. Most commercial and federally funded insurance plans cover cancer predisposition testing when criteria are met, with many patients having no out-of-pocket costs.
- Minimally Invasive Procedures: Revenue from focal therapy treatments including Laser Focal Therapy (LFT), TULSA-PRO ablation, and BPH treatments. These are performed as outpatient procedures at partner centers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | One-time | Insurance-covered genetic testing for qualifying patients |
| Other | One-time | Self-pay options for uninsured or underinsured patients |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
HALO Diagnostics product offering
Product offeringCore offering
HALO Diagnostics provides precision diagnostic services combining advanced imaging (mpMRI, PET/CT, 3D mammography), genetic and genomic testing, and MRI-guided minimally invasive treatments for early detection of cancer, cardiovascular disease, and dementia. Services are delivered through a network of partner imaging and treatment centers across the United States, including Genetic Testing Centers and Focal Therapy Centers, serving patients directly and via physician referrals.
Product overview
HALO Diagnostics is a precision diagnostics company offering a comprehensive ensemble of diagnostic services and minimally invasive treatments organized around three core disease areas: cancer, cardiovascular disease, and dementia. The company operates a 'Imaging Center 2.0' model that transforms traditional imaging centers into next-generation diagnostic hubs. Core products and services include advanced imaging (MRI, CT, PET/CT, 3D mammography), genetic and genomic testing (cancer predisposition testing, BRCA, ExoDx, Decipher), MRI-guided prostate focal therapy procedures (Laser Focal Therapy and TULSA-PRO), multi-parametric MRI for prostate cancer screening and active surveillance, dementia diagnostics using Icobrain volumetric MRI analysis and amyloid/tau PET imaging, PSMA PET imaging with PYLARIFY, and biomarker testing. Services are delivered through a network of partner locations including Genetic Testing Centers and Focal Therapy Centers across the nation.
Differentiator
Problem solved
Functional benefit
Brands
- Prostate Cancer Institute: Comprehensive men's health program focusing on prostate cancer screening, diagnosis, and treatment.
- Scionti Prostate Center
- Prostate Laser Center
- Precision Imaging Centers
- HALO Breast Care Center
- Imaging Center 2.0
Products and services
- Cancer Genetic Testing Genetic testing services for cancer risk assessment including BRCA gene testing, PALB2 variant detection, and family history-based screening to identify hereditary cancer risk factors for individuals concerned about cancer risk.
- Cardiovascular Disease Screening Early detection services for cardiovascular disease including blood pressure screening, cholesterol testing, and advanced cardiac imaging to identify risk factors before serious cardiac events occur, for individuals with cardiovascular risk factors.
- Dementia Early Detection Comprehensive dementia and Alzheimer's disease early detection using advanced imaging and biomarker testing to identify cognitive decline in early stages when treatment is most effective, for individuals with cognitive concerns or family history.
- Prostate Focal Therapy Minimally invasive prostate cancer and BPH treatment program including MRI-guided laser focal therapy and TULSA-PRO transurethral ultrasound ablation for targeted prostate tissue ablation, for men with prostate cancer or BPH.
- TULSA-PRO Treatment Transurethral ultrasound ablation procedure for prostate cancer and BPH that uses real-time MRI guidance and robotically-driven directional thermal ultrasound to deliver predictable ablation of targeted prostate tissue without incisions or radiation, for men with prostate cancer or BPH.
- Laser Focal Therapy MRI-guided laser focal therapy using a thin laser fiber (1.85mm) inserted through the rectum into the prostate for precise ablation of prostate cancer and BPH tissue while preserving neurovascular bundles and ejaculatory ducts, for men with localized prostate cancer.
- Active Surveillance with mpMRI Multi-parametric MRI-based prostate cancer surveillance program for men with low-risk cancer, enabling non-invasive monitoring of disease progression and reducing unnecessary biopsies.
- Advanced Imaging Services Comprehensive imaging services including MRI scans, CT scans, PET/CT scans, ultrasound scans, coronary CT angiography, virtual colonoscopy, whole body MRI screening, and traumatic brain injury imaging, for patients requiring advanced diagnostic imaging.
- Dementia & Alzheimer's Imaging Diagnostics Advanced brain imaging services including volumetric MRI analysis using Icobrain DM, FDG-PET/CT for glucose metabolism assessment, Amyvid amyloid PET imaging, and TAUVID tau tangle imaging for comprehensive dementia diagnosis, for patients with cognitive concerns.
- Biopsy & Aspiration Services Advanced biopsy services including MRI-guided prostate biopsy, targeted biopsies for various cancer types, and aspiration procedures performed with image guidance for precise tissue sampling, for patients requiring tissue diagnosis.
- Interventional Radiology & Pain Management Image-guided interventional procedures including facet injections and other pain management treatments using advanced radiology guidance for precise delivery, for patients requiring interventional pain management.
- 3D Mammography / Tomosynthesis 3D breast imaging technology that creates detailed cross-sectional images of the breast for enhanced cancer detection rates and fewer recall appointments compared to standard mammography, for women undergoing breast cancer screening.
- PSMA PET Imaging with PYLARIFY Prostate-specific membrane antigen (PSMA) PET imaging using PYLARIFY contrast agent for detection and localization of metastatic and recurrent prostate cancer in lymph nodes, bone, and soft tissue, for men with suspected metastatic or recurrent prostate cancer.
- Biomarker & Genomic Testing Comprehensive biomarker, genetic, and genomic testing services including ExoDx urine test for aggressive prostate cancer risk, BRCA testing, Decipher Prostate genomic test for tumor metastatic potential assessment, and multiomics analysis, for patients seeking molecular risk profiling.
- Imaging Center 2.0 Next-generation diagnostic hub model transforming traditional imaging centers into comprehensive precision diagnostics facilities offering integrated imaging, genomics, and molecular diagnostics, for imaging center operators and healthcare systems.
Quantifiable outcome
- 5x higher survival rate for cancer patients diagnosed at early stage vs advanced stage
- +6 more outcomes
Companies that use HALO Diagnostics
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles4 records
HALO Diagnostics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature8 records
HALO Diagnostics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- IncellDxcoreHALO Diagnostics partnered with IncellDx, a single-cell molecular diagnostics company, to develop innovative testing for prostate and bladder cancers. The partnership combines HALO's advanced imaging and molecular diagnostics with IncellDx's screening technology including molecular assay kits that analyze urine samples with speed, scale, and molecular resolution for diagnostic and treatment decisions.
- Genomic Testing Cooperative (GTC)coreHALO Diagnostics partnered with Genomic Testing Cooperative to offer innovative personalized testing combining HALO's clinical ensemble and image-guided therapies with GTC's genomic profiling of patient DNA/RNA using liquid biopsy and tissue samples. The partnership provides comprehensive biomarker testing for treatment decision-making in prostate, breast, and lung cancers. GTC's Liquid Trace liquid biopsy test combining cell-free DNA and cell-free RNA is now available to HALO patients.
Scale indicators3 records
Recent moves6 records
Expansion highlights7 records
HALO Diagnostics competitors and assessment
Company assessmentEmerging players
- Tempus: AI-powered precision medicine company combining genomic sequencing, imaging data, and clinical data to enable personalized treatment decisions. Comparable to HALO's imaging + omics + AI thesis and overlapping with HALO's Decipher and Genomic Testing Cooperative partnerships; Tempus is a much larger and broader competitor in the precision diagnostics stack.
- Veracyte: Genomic diagnostics company focused on urologic cancers (Decipher Prostate), thyroid, and lung. Highly comparable in HALO's Decipher Prostate genomic test offering and prostate cancer diagnostic pathway; both target urology and oncology channels with molecular testing positioned alongside imaging.
- Natera: Genetic testing and liquid biopsy company offering oncology, reproductive health, and organ health tests. Comparable in the genomic and hereditary cancer testing layer of HALO's offering (BRCA, cancer predisposition panels); both serve similar at-risk patient populations via physician ordering workflows.
- Guardant Health: Precision oncology company focused on liquid biopsy and genomic profiling for cancer detection and monitoring. Comparable through HALO's GTC partnership and IncellDx collaboration, which similarly target liquid biopsy and molecular profiling for cancer risk and treatment selection; Guardant is a deeper-pocketed competitor in the genomic layer HALO integrates.
- NeoGenomics: Specialty oncology and clinical diagnostics laboratory offering comprehensive genomic profiling and hematology/oncology testing. Comparable to HALO's molecular diagnostics layer via GTC partnership; NeoGenomics serves similar oncology and urology referral channels.
Direct peers
- Icometrix: AI-driven brain MRI analysis company whose Icobrain DM platform powers HALO's dementia volumetric reporting. Comparable as an enabling technology partner and adjacent AI-imaging-software peer for dementia and neurodegeneration quantification; serves overlapping neurology and radiology customer base.
Broad incumbents
- Akumin: Outpatient diagnostic imaging operator with MRI, CT, PET/CT, ultrasound, and X-ray across multiple US states. Comparable as a multi-site diagnostic imaging services company with similar modality mix and payor mix to HALO, but broader portfolio and less specialty depth in prostate/genomic diagnostics.
- SimonMed Imaging: One of the largest outpatient imaging networks in the US, offering MRI, CT, PET/CT, 3D mammography, and specialty imaging. Comparable as a regional-to-national diagnostic imaging services peer with overlapping modalities (3D mammography, MRI) and similar physician-referral GTM, though SimonMed lacks HALO's focal therapy and genomic integration.
- RadNet: Large national diagnostic imaging chain operating fixed-site MRI, CT, PET/CT, and mammography centers. Comparable as a multi-modality outpatient imaging services provider to HALO's imaging center footprint, though RadNet's scale and focus on general radiology means HALO competes in the same patient acquisition channels but at higher acuity and price points.
- US Radiology Specialists: National physician-led radiology practice partnering with hospital systems and operating outpatient imaging centers. Comparable as a multi-state diagnostic imaging services platform; HALO is differentiated by its proprietary precision diagnostic ensemble and specialty prostate offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Customer concentration
HALO Diagnostics social profiles
Digital presenceHALO Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
HALO Diagnostics leadership team
Management profileNumber of profiles
Profiles5 records
HALO Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HALO Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HALO Diagnostics
What does HALO Diagnostics do?
HALO Diagnostics provides precision diagnostic services combining advanced imaging (mpMRI, PET/CT, 3D mammography), genetic and genomic testing, and MRI-guided minimally invasive treatments for early detection of cancer, cardiovascular disease, and dementia. Services are delivered through a network of partner imaging and treatment centers across the United States, including Genetic Testing Centers and Focal Therapy Centers, serving patients directly and via physician referrals.
Is HALO Diagnostics a public or private company?
HALO Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.
When was HALO Diagnostics founded?
HALO Diagnostics was founded in 2023. It employs 101 to 250 people.
Where is HALO Diagnostics based?
HALO Diagnostics is headquartered in Menlo Park, United States, in the North America region.
How does HALO Diagnostics make money?
Three revenue lines are on record. Diagnostic Imaging Services are the primary driver. The others are genetic and Genomic Testing and minimally Invasive Procedures.
Who are HALO Diagnostics's main competitors?
Emerging players on record are Tempus, Veracyte, Natera, Guardant Health and NeoGenomics. Icometrix is listed as a direct peer. Broad incumbents are Akumin, SimonMed Imaging, RadNet and US Radiology Specialists.
Does HALO Diagnostics have an API?
No public API is recorded for HALO Diagnostics.
What industry is HALO Diagnostics in?
HALO Diagnostics's product category is Precision Diagnostics. Its primary akta.pro industry code is HLAFAKAB, Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology), with a secondary code of HLAKABAE, Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear). Its NAICS code is 621512 and its SIC code is 8000.